Core Viewpoint - The collaboration between Shanghai Ruizhi Pharmaceutical Research Group and East China Normal University aims to advance drug discovery and delivery systems through the establishment of a cutting-edge technology joint laboratory, focusing on antibody-drug conjugates (ADC) and nucleotide monomer synthesis systems [1] Group 1: Collaboration and Research Focus - The partnership is based on a strategic cooperation framework agreement, emphasizing joint research in drug discovery, biochips, drug delivery systems, and drug conjugates [1] - The newly developed automated, intelligent, and integrated desktop synthesis systems for ADC and nucleotide monomers enable seamless transition from laboratory research to industrial production [1] Group 2: Technological Advancements - The ADC microfluidic manufacturing system integrates ultra-fast laser microfluidic chips with intelligent process control, transitioning antibody drug conjugation from intermittent operations to platform-based manufacturing [1] - The nucleotide monomer microfluidic synthesis system utilizes a catalyst-free and base-free "intelligent microfluidic" approach for the continuous, stable, and green synthesis of phosphoramidite monomers, establishing new standards for the supply of nucleic acid drug materials [1] Group 3: Impact on R&D Efficiency - The implementation of these automated and intelligent synthesis systems is expected to significantly shorten research and development cycles and enhance R&D efficiency, ultimately providing better services to clients [1]

Core Viewpoint - The company has established a cutting-edge technology joint laboratory with East China Normal University to enhance research in drug discovery, biochips, drug delivery systems, and drug conjugates (XDC) [1] Group 1: Collaboration and Research Development - The collaboration is based on a strategic cooperation framework agreement, aiming to advance research in various pharmaceutical fields [1] - The joint efforts have led to the successful development of an automated, intelligent, and integrated desktop synthesis system for antibody-drug conjugates (ADC) and nucleotide monomers [1] Group 2: Technological Advancements - The ADC microfluidic manufacturing system integrates ultra-fast laser microfluidic chips with intelligent process control, transitioning antibody drug conjugation from "batch operation" to "platform-based intelligent manufacturing" [1] - The nucleotide monomer microfluidic synthesis system utilizes a "smart microfluidic" approach without catalysts or alkali participation, enabling continuous, stable, and green synthesis of phosphoramidite monomers [1] Group 3: Impact on R&D Efficiency - The implementation of these automated and intelligent synthesis systems is expected to significantly shorten research and development cycles and enhance R&D efficiency [1] - This advancement will allow the company to provide higher quality services to its clients [1]